No abstract

No abstract

Introduction. Aggressive B-cell lymphomas are a heterogeneous group of diseases with various clinical, patohistological, genetic characteristics and a variety of treatment outcomes. Diffuse large B-cell lymphoma is the most common lymphoma in European countries, some lymphomas are recognized as specifically aggressive, providing non-adequate response to the standard treatment (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). High-grade B-lymphomas. One group consists of those which are carriers of the c-myc, bcl-2 or bcl-6 rearrangement established by Fluorescence in situ hybridization, and are called high grade B lymphomas, which can be double hit or triple hit. The other group consists of those with blastoid morphology, which are not carriers of the c-myc, bcl-2 and bcl- 6 rearrangement and are called Not Otherwise Specified. This heterogeneous group is a carrier of a single myc mutation in 45% of cases, in 15% of patients, an additional analysis of gene expression profiling indicates the presence of high grade B lymphomas double hit sig+. Extranodal localization with Central Nervous System involvement is frequently reported. Clinical staging and disease progression along with risk assessment by means of IPI scores and aaIPI scores in patients with high-grade B-lymphomas. Diagnostic procedures during the clinical interview, physical examination, laboratory analyses and various additional diagnostic procedures. High-grade Blymphomas treatment. Studies indicate more intensive induction chemotherapy including central nervous system prophylaxis for these patients. Conclusion. The question of how to choose the most effective therapeutic strategy in high grade B lymphomas is still open at this moment, and examinations are focused on the research of molecular mechanisms of lymphomagenesis.

No abstract

Thrombophilia is a condition of enhanced functionality of the haemostatic system with an increased tendency for thrombosis, and it can be a congenital, acquired, or complex defect. Pregnancy can be the cause of acquired transitory thrombophilia, which may lead to complications if inherited thrombophilia is also present.The aim of this study was to determine the genetic structure of the population based on the frequency of the gene variants factor V Leiden G1691A, factor II G20210A, methylenetetrahydrofolate reductase C677T, and plasminogen activator inhibitor-1 4G/5G, as well as to investigate the predictive value of these gene variants in repeated miscarriages.The study included 87 female patients from Central Serbia with an average age of 32.7±4.5 years with inherited thrombophilia and previous miscarriages, with or without intrauterine foetal death. The exclusion criteria included the existence of gynaecological and infectious aetiology and the deficit of factors important for the coagulation process.The resulting genotypes were in Hardy-Weinberg equilibrium. The frequency of genotypes with mutated alleles was significantly higher in this group of patients than in the control group for all variants except factor II G20210A. The most commonly mutated alleles were the plasminogen activator inhibitor-1 4G allele (0.61) and methylenetetrahydrofolate reductase T allele (0.47). Double mutation of plasminogen activator inhibitor-1 4G/5G and methylenetetrahydrofolate reductase C677T was dominant in patients with recurrent pregnancy loss (46.15%).The presence of a combination of genetic variants of the plasminogen activator inhibitor-1 4G/5G and methylenetetrahydrofolate reductase C677T is a significant predictor of spontaneous abortions in women with inherited thrombophilia in Central Serbia.